A secondary analysis of a phase III randomised trial was performed. The initial trial was comparing capecitabine and oxaplatin with or without lapatinib for treatment of advanced gastroesophageal cancer.
Good news in the field of malaria treatment in South Africa. Garsun® (artesunate; from Equity Pharmaceuticals) is now registered in South Africa.
With little evidence that failing to complete a prescribed antibiotic course contributes to resistance, it’s time to drop this message, argue Martin Llewelyn et al in a piece in the BMJ last month.